Education

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of Health

Opportunity #: PAR-25-070

Award Ceiling

N/A

Award Floor

N/A

Close Date

Jan 7, 2027

92 days left

Total Funding

N/A

Posted Date

Nov 18, 2024

Cost Sharing Required

Grants.gov ID

357203

Description

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Eligible Applicants

State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and state-controlled institutions of higher education; Federally recognized Native American tribal governments; Public housing authorities or Indian housing authorities; Native American tribal organizations other than governments; Nonprofits with 501(c)(3) status; Nonprofits without 501(c)(3) status; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Other applicants

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.